Middle East and Africa Cell and Gene Therapy Manufacturing Market: Industry Trends and Future Forecast, Till 2035 - Distribution by Type of Therapy, Type of Scale, Type of Workflow, Type of Process, Type of Technology, End User and Leading Players

Description

Middle East and Africa Cell and Gene Therapy Manufacturing Market: Overview

As per Roots Analysis, the Middle East and Africa cell and gene therapy market is estimated to grow from USD 223 million in the current year to USD 848 million by 2035 at a CAGR of 16% during the forecast period, till 2035.

Middle East and Africa Cell and Gene Therapy Manufacturing Market - IMG1

Middle East and Africa Cell and Gene Therapy Manufacturing Market: Growth and Trends

Cell and gene therapies represent a class of advanced therapeutics demonstrating strong potential in the treatment of rare diseases, oncology indications, and chronic conditions. These therapies are strategically engineered to minimize off-target effects while enabling precise intervention at the cellular level. Key advantages include targeted therapeutic action, tissue regeneration and repair, the potential to slow or halt the progression of genetic disorders, and the ability to address specific genes that are dysfunctional or mutated.

The cell and gene therapy industry in the Middle East and Africa (MEA) is emerging as a high-growth sector, transitioning from nascent R&D to scaled manufacturing and clinical adoption through government-backed infrastructure and global partnerships. Current trends in the Middle East and Africa (MEA) cell and gene therapy manufacturing market emphasize rapid infrastructure expansion, automation adoption, and a surge in CDMO outsourcing, driven by clinical trial growth and government-backed biotech hubs. Owing to the abovementioned developments, the Middle East and Africa cell and gene therapy market is poised for notable future growth during the forecast period.

Growth Drivers: Strategic Enablers of Market Expansion

The market for cell and gene therapy in the Middle East and Africa (MEA) is expanding rapidly due to numerous factors such as demographic pressures (such as a growing population, increasing life expectancy), strategic government incentives, and technology development catered to local healthcare needs. One of the primary market growth drivers is the growing number of chronic illnesses, such as cancer, and uncommon genetic diseases that afflict millions of people. Other indications such as metabolic and ophthalmologic abnormalities require novel, one-time curative remedies that extend beyond traditional therapies. Based on the abovementioned factors, the MEA cell and gene therapy market is expected to witness sustained growth in the coming years.

Market Challenges: Critical Barriers Impeding Progress

Challenges persist in the cell and gene therapy market in the Middle East and Africa (MEA) despite the ongoing market growth, hindering faster adoption. High treatment costs, which are frequently unaffordable in environments with limited resources, restrict patient access. This worsens by the intricacy of customized manufacturing procedures that call for strict quality control for vectors, batch testing, and gene editing validation. Further, fragmented regulatory frameworks across diverse countries also create hurdles in approvals and standardization. Owing to these challenges, industry stakeholders have redirected their attention towards enhancing the manufacturing processes for cell and gene therapies.

Cell Therapies: Leading Market Segment

According to our estimates the production of cell therapies represents the biggest share (~60%) of the market. This is because of the increasing focus on developing cell-based therapies such as CAR-T cell treatments to tackle different diseases (especially cancer). Further, it is important to highlight that the gene therapies sector will demonstrate substantial growth opportunities and is expected to increase at a higher CAGR during the forecast period. Gene therapies have demonstrated strong efficacy in disease treatment and in slowing or halting disease progression, alongside increasing research focused on understanding genetic mutations and assessing the potential of gene-based interventions for effective disease management.

Research and Development: Dominating Market Segment

At present, the research and development sector leads the market, representing nearly 70% of the total share. Numerous factors, including a growing pipeline of cell and gene therapies along with heightened investments in research and development for large-scale production, drive the market share. However, the commercial-scale production segment is expected to grow at a higher CAGR throughout the forecast period. This can be attributed to the rising demand for the cell and gene therapies owing to the high prevalence of cancer, rare genetic disorders, and chronic diseases affecting millions in the region, necessitating scalable local production over reliance on imports.

Middle East and Africa Cell and Gene Therapy Manufacturing Market: Key Segments

Type of Therapy

Cell Therapies (Stem Cell Therapy and Non-Stem Cell Therapy)
Gene Therapies

Type of Scale

Precommercial / R&D Scale Manufacturing
Commercial Scale Manufacturing

Type of Workflow

C Cell Processing
Cell Banking
Process Development
Fill & Finish Operations
Analytical & Quality Testing
Raw Material Testing
Vector Production
Other Workflow

Type of Process

Upstream Processes
Downstream Processes

Type of Technology

Fluorescence-Activated Cell Sorting (FACS)
Enzyme-Linked Immunosorbent Assay (ELISA)
Chromatography
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Other Technologies

End User

Pharmaceutical Companies
Biopharmaceutical / Biotechnological Companies
Contract Manufacturing Organizations

Example Players in the Middle East and Africa Cell and Gene Therapy Manufacturing Market

Catalent
Charles River Laboratories
Lonza
Merck
Thermo Fisher Scientific
WuXi AppTec

Key Questions Answered in this Report

How many Middle East and Africa cell and gene therapy manufacturers are currently engaged in this market?
Which are the leading companies in this market?
Which country dominates the Middle East and Africa cell and gene therapy market?
What are the key trends observed in the Middle East and Africa cell and gene therapy market?
What factors are likely to influence the evolution of this market?
What are the primary challenges faced by Middle East and Africa cell and gene therapy manufacturers?
What is the current and future Middle East and Africa cell and gene therapy market size?
What is the CAGR of Middle East and Africa cell and gene therapy market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
The report allows for more effective communication with the audience and in building strong business relations.

Complementary Benefits

Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RAD00008

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Value and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product (GDP)
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross-Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Chapter Overview
6.2. Overview of Cell and Gene Therapies
6.3. Classification of Cell and Gene Therapies
6.4. Therapeutic Areas Targeted by Cell and Gene Therapies
6.5. Challenges in the Cell and Gene Therapy Domain
6.6. Recent Developments in the Cell and Gene Therapy Domain

7. MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Middle East and Africa Cell and Gene Therapy Market: Overall Market Landscape
- 7.2.1. Analysis by Year of Establishment
- 7.2.2. Analysis by Company Size
- 7.2.3. Analysis by Location of Headquarters
- 7.2.4. Analysis by Location of Manufacturing Facility
- 7.2.5. Analysis by Source of Cells
- 7.2.6. Analysis by Scale of Operation
  - 7.2.6.1. Analysis by Type of Additional Service Offered

8. COMPANY PROFILES: MIDDLE EAST AND AFRICA CELL AND GENE THERAPY MARKET

8.1. Chapter Overview
8.2. Lonza
- 8.2.1. Company Overview
- 8.2.2. Product Portfolio
- 8.2.3. Financial Information
- 8.2.4. Recent Developments and Future Outlook
8.3. Thermo Fisher Scientific
8.4. Merck
8.5.Catalent
8.6. Charles River Laboratories
8.7. Wuxi AppTec

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview
9.2. Partnership Models
9.3. Middle East and Africa Cell and Gene Therapy Manufacturers: Partnerships and Collaborations
- 9.3.1. Analysis by Year of Partnership
- 9.3.2. Analysis by Type of Partnership
- 9.3.3. Most Active Players: Analysis by Number of Partnerships
- 9.3.4. Analysis by Geography
  - 9.3.4.1. Intercontinental and Intracontinental Agreements
  - 9.3.4.2. Local and International Agreements

10. MARKET IMPACT ANALYSIS

10.1. Chapter Overview
10.2. Market Drivers
10.3. Market Restraints
10.4. Market Opportunities
10.5. Market Challenges
10.6. Conclusion

11. MIDDLE EAST AND AFRICA CELL AND GENE THERAPY MANUFACTURING MARKET

11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Middle East and Africa Cell and Gene Therapy Market: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
11.4. Roots Analysis Perspective on Market Growth
11.5 Scenario Analysis
- 11.5.1. Conservative Scenario
- 11.5.2. Optimistic Scenario
11.6. Key Market Segmentations

12. MIDDLE EAST AND AFRICA CELL AND GENE THERAPY MARKET, BY TYPE OF THERAPY

12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Middle East and Africa Cell and Gene Therapy: Distribution by Type of Therapy
- 12.3.1. Cell Therapies, Historical Trends (Since 2022) and Forecasted (Till 2035)
- 12.3.2. Gene Therapies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
12.4. Data Triangulation and Validation

13. MIDDLE EAST AND AFRICA CELL AND GENE THERAPY MARKET, BY TYPE OF SCALE

13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Middle East and Africa Cell and Gene Therapy Market: Distribution by Type of Scale
- 13.3.1. Precommercial / R&D Scale Manufacturing: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 13.3.2. Commercial Scale Manufacturing: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
13.4. Data Triangulation and Validation

14. MIDDLE EAST AND AFRICA CELL AND GENE THERAPY MARKET, BY TYPE OF WORKFLOW

14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Middle East and Africa Cell and Gene Therapy Market: Distribution by Type of Offering
- 14.3.1. C Cell Processing: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 14.3.2. Cell Banking: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 14.3.3. Process Development: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 14.3.4. Fill & Finish Operations: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 14.3.5. Analytical & Quality Testing: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 14.3.6. Raw Material Testing: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 14.3.7. Vector Production: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 14.3.8. Other Workflow: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
14.4. Data Triangulation and Validation

15. MIDDLE EAST AND AFRICA CELL AND GENE THERAPY MARKET, BY TYPE OF PROCESS

15.1. Chapter Overview
15.2. Assumptions and Methodology
15.3. Middle East and Africa Cell and Gene Therapy Market: Distribution by Type of Process
- 15.3.1. Upstream Process: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 15.3.2. Downstream Process: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
15.4. Data Triangulation and Validation

16. MIDDLE EAST AND AFRICA CELL AND GENE THERAPY MARKET, BY TYPE OF TECHNOLOGY

16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Middle East and Africa Cell and Gene Therapy Market: Distribution by Type of Technology
- 16.3.1. Fluorescence-Activated Cell Sorting (FACS): Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 16.3.2. Enzyme-Linked Immunosorbent Assay (ELISA): Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 16.3.3. Chromatography: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 16.3.4. Next-Generation Sequencing (NGS): Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 16.3.5.. Polymerase Chain Reaction (PCR): Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 16.3.6. Other Technologies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.4. Data Triangulation and Validation

17. MIDDLE EAST AND AFRICA CELL AND GENE THERAPY MARKET, BY END USER

17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Middle East and Africa Cell and Gene Therapy Market: Distribution by End User
- 17.3.1. Pharmaceutical Companies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 17.3.2. Biopharmaceutical / Biotechnological Companies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
- 17.3.3. Contract Manufacturing Organizations: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.4. Data Triangulation and Validation